RBC Maintains Outperform on Bausch + Lomb Corporation (BLCO) Mar 17, 2026
RBC Capital on March 17, 2026 maintained an Outperform rating on Bausch + Lomb Corporation (BLCO). The BLCO analyst rating was left unchanged after RBC said a delay in anticipated US Rx DED competition is neutral to slightly positive for Bausch + Lomb. The note did not include a new price target. We review the rating action, explain what it means for investors, and connect the note to short-term stock movement and longer-term coverage trends.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
